Cochrane · systematic review · CD013079
Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
Frost, F, Shaw, M, Nazareth, D · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings ‐ AZLI compared with placebo for chronic Burkholderia cepacia complex infection in people with CF
Population: adults and children with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relative change in FEV1% predicted Summary of findings ‐ AZLI vs placebo | no estimate extracted | 1 study · 99 participants | Moderate Downgraded: imprecision |
Days to next exacerbation Summary of findings ‐ AZLI vs placebo | no estimate extracted | 1 study · 100 participants | Moderate Downgraded: imprecision |
Participants hospitalised for respiratory exacerbation Summary of findings ‐ AZLI vs placebo | RR 0.88 [0.53, 1.45] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Any AEs Summary of findings ‐ AZLI vs placebo | RR 1.08 [0.98, 1.19] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Mortality Summary of findings ‐ AZLI vs placebo | RR 5.41 [0.27, 109.87] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Summary of findings ‐ AZLI compared with placebo for chronic Burkholderia cepacia complex infection in people with CF
Population: adults and children with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relative change in FEV1% predicted Summary of findings ‐ AZLI vs placebo | no estimate extracted | 1 study · 99 participants | Moderate Downgraded: imprecision |
Days to next exacerbation Summary of findings ‐ AZLI vs placebo | no estimate extracted | 1 study · 100 participants | Moderate Downgraded: imprecision |
Participants hospitalised for respiratory exacerbation Summary of findings ‐ AZLI vs placebo | RR 0.88 [0.53, 1.45] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Any AEs Summary of findings ‐ AZLI vs placebo | RR 1.08 [0.98, 1.19] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Mortality Summary of findings ‐ AZLI vs placebo | RR 5.41 [0.27, 109.87] | 1 study · 100 participants | Moderate Downgraded: imprecision |